Quality and Regulatory Sourcebook March 2022
Read the article:
A New Route to Pharma GDP Compliance and Standardization
Read the eBook:
BioPharm International's Quality and Regulatory Sourcebook eBook
CONTINUE TO SITE
OR WAIT null SECS
Advertisement
- About Us
- Advertise
- Editorial Information
- Contact Us
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2024 MJH Life Sciences™ and BioPharm International. All rights reserved.
A New Route to Pharma GDP Compliance and Standardization
Published on:
Courtney Soulsby, Alan Kennedy
BioPharm International, BioPharm International, Regulatory Sourcebook March 2022, Volume 2022 eBook, Issue 1
Pages: 24-29
A consensus-based approach to GDP lies at the heart of a new industry-wide program seeking to rationalize, standardize, and harmonize the adherence to pharma transportation norms and regulatory guidelines.
The logistics associated with the safe and efficient physical transportation of pharmaceuticals is increasingly taxing the minds of logisticians as medicines become more complex and labile and their regulatory oversight intensifies. The statutory need to maintain the therapeutic and physical integrity of drugs during transit renders the management of quality and the adherence to good distribution practice (GDP) guidelines an absolutely critical part of the pharmaceutical supply process.
Read this article in Pharmaceutical Technology’s March 2022 Quality and Regulatory Sourcebook eBook.
About the author
Courtney Soulsby is sector director, Healthcare & Life Sciences, BSI.
Advertisement
Alan Kennedy is director, Team Poseidon.
Article Details
BioPharm International eBook: Quality and Regulatory Sourcebook, March 2022 Pages: 24–29
Citation
When referring to this article, please cite it as C. Soulsby, A. Kennedy, “A New Route to Pharma GDP Compliance and Standardization," BioPharm International Quality and Regulatory Sourcebook eBook (March 2022).
